Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1β in the synovium
- 1 February 2013
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 72 (2) , 250-257
Abstract
Objective To explore the disease-modifying effect, under therapeutic conditions, of strontium ranelate (SrRan) on the progression of joint structural changes and on the major pathophysiological pathways in an experimental osteoarthritis dog model. Methods Dogs underwent sectioning of the anterior cruciate ligament, and 4 weeks after surgery received oral treatment of SrRan 25, 50 or 75 mg/kg per day, or placebo for 12 weeks. Methods included macroscopy, picrosirius red staining, histology, subchondral bone histomorphometry, quantitative PCR, and ELISA for CTX-II level in serum. Strontium plasma and synovial fluid levels were also measured. Results At steady state, strontium blood exposures were within the clinical therapeutic range of osteoarthritis patients and correlated with strontium concentrations in synovial fluid. SrRan treatment significantly reduced the osteoarthritis cartilage lesions at all doses tested (p≤0.05). Significantly better preservation of the collagen network was also found in SrRan-treated dogs at 50 and 75 mg/kg per day (p=0.03). The osteoarthritis subchondral bone thickening observed in osteoarthritis-placebo dogs was significantly reduced by SrRan at 50 mg/kg per day (p=0.02). The increased gene expression levels of MMP-1, MMP-13 and cathepsin K in osteoarthritis cartilage were all significantly reduced by SrRan at 75 mg/kg per day (p≤0.03) as were, in osteoarthritis synovium, IL-1β at 50 and 75 mg/kg per day (p=0.05) and MMP-3 at all doses tested (p≤0.02). The serum level of CTX-II was reduced (p≤0.04) by SrRan at 16 weeks in dogs treated with 50 and 75 mg/kg per day. Conclusions This study is the first to demonstrate in vivo in an animal model that SrRan reduced the progression of osteoarthritis structural changes. The inhibition of several key proteases as well as IL-1β may have contributed to the beneficial effect of SrRan.Keywords
This publication has 35 references indexed in Scilit:
- Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosisOsteoporosis International, 2011
- Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament modelArthritis Research & Therapy, 2011
- A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®Osteoporosis International, 2011
- Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritisClimacteric, 2010
- Enhancement of intervertebral disc cell senescence by WNT/β‐catenin signaling–induced matrix metalloproteinase expressionArthritis & Rheumatism, 2010
- OARSI recommendations for the management of hip and knee osteoarthritisOsteoarthritis and Cartilage, 2010
- Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13Arthritis Research & Therapy, 2009
- Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: Prominent role of Wnt‐induced signaling protein 1Arthritis & Rheumatism, 2009
- Effects of strontium ranelate on spinal osteoarthritis progressionAnnals of the Rheumatic Diseases, 2008
- A longitudinal study of subchondral plate and trabecular bone in cruciate‐deficient dogs with osteoarthritis followed up for 54 monthsArthritis & Rheumatism, 1993